2025 Q4 -tulosraportti
21 päivää sitten
‧32 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 2 913 | - | - | ||
| 12 126 | - | - | ||
| 1 000 | - | - | ||
| 3 727 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 85 506 | 85 506 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 85 506 | 85 506 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenFollowing my post on 8. March, management's shareholdings in BioPorto are a strong optimistic signal, as stated in Carnegie's report page 48. Among the company's ten largest shareholders are CEO, CLO, former CEO, chairman and vice charirman. The ten largest shareholders hold approx. 33%. Since Martin Bundgaard first flagged his 5% on Monday, they are not included in Carnegie's overview. From my post on 8. March: 2026 could be a very good year for BioPorto: The sentiment for biotech on Wall Street has turned significantly at the beginning of 2026, and the IPO market (initial public offerings) shows clear signs of life after several years of dormancy. After a very quiet 2024 and a historically weak 2025, investors have returned with renewed optimism. The Chairman, Jens Due Olsen, has invested approx. 6 million kr. of his own funds in 2025 (at prices 1.34 and 1.07 in the two emissions). Remarkable for a company of BioPorto's size. * Signal: Chairmen in biotech companies rarely make million-dollar investments shortly before crucial clinical data, unless they have a very strong belief in the company's fundamental value and the preliminary observations from the studies. * Risk/Reward: He bought in at a time when the stock is close to its historical low, which suggests that he sees a significant asymmetric gain opportunity when the adult data is expected to land later in 2026 Carsten Buhl joined on 1. September 2025, as the new CEO, and already in November chose to invest approx. 500,000 kr. in the emission. * Insight: As CEO, he has direct responsibility for the execution of the clinical study for adults. His willingness to invest his own money so quickly after his employment is interpreted as him "liking what he sees" in the internal processes and in the dialogue with the American clinics.
·1 päivä sitten · MuokattuFurther to your post Preston20, I would like to inform that it is known to those of us who have been with the stock for a longer time, that there are several people who comment on Bioporto because they at some point lost money on this stock. Instead of taking the loss like adult men, they lie down on their stomachs and pound their fists on the floor and cry like small annoying curling children, who again, and again and again, involve the rest of us in their losses, back when the king of clubs was a knave. Lord preserve us.
·11 t sitten3d We are merely commenting on facts about a company that is not developing .... and patents that are soon expiring- ·1 päivä sitten
·3 päivää sittenUntil the company can clearly demonstrate through large studies precisely how, and especially why in terms of more effective treatment and savings, the product should be used, it will not be sold in larger numbers. The test costs a fortune compared to the existing one, and there is no medicine one can give in connection with acute kidney injury - so why exactly use it, when fluids and medication will already be regulated? The product, after almost 15 years available and attempted to be sold, would sell itself, where the opposite is still the case, if it both saved lives and resulted in savings, but that is far from documented. Should it succeed in documenting the effect in a few years, the major players can simply offer a similar product, as the patents begin to expire this year.- ·3 päivää sittenK1000 I think it's strange that you start discussing Bioporto, on another stock's page. You are apparently in doubt whether I know Bioporto's path to an FDA approval for children. The short version of why Bioporto chose to split the NGAL test into two. One for children and one for adults. Bioporte had for an incredibly many years tried to get the NGAL test approved in the USA, as a combined test, but was rejected, with a standard text, that there was not enough evidence etc. Only when Antony became CEO, (he is a US citizen) did he get a dialogue with the FDA, and here the FDA suggested that if Bioporto were to have a chance of getting an approval, the test should be split into two, as it is today. The FDA stipulated that it should be the children's test they should run through a study first, if the FDA were to receive an application form. So it was not by Bioporto's good will or suggestion that the test was split into two, it was the FDA that suggested it, and it was the FDA that stipulated that it should be the test for children that they would look at first. When the FDA says jump, you ask how high. There are several webcasts where PME details the process with the FDA. You'll have to find them yourself on You tube.·1 päivä sitten@3D... I apologize if my reply in Acucort (the forum) came across as if I wanted to discuss bioporto. That was not the intention, but when you wrote that an FDA application would now take a long time, because the FDA had decided to divide the study into a pediatric and an adult study respectively, I got the idea that you were confusing acucort's situation with bioporto's ditto; which you also agreed with me on. Perhaps I should not have elaborated on how and why the two situations are different, but merely stuck to explaining what you had misunderstood regarding acucort's application process. I then forgot the latter part here in my first reply, but wrote it shortly after in another. I don't think I expressed that I doubt whether you are familiar with bioporto's application process… and I naturally have nothing against debate participants maintaining optimism regarding the companies they are invested in, but if I'm to be completely honest, it's a bit difficult to read post after post where you distort realities, so that reality appears brighter for bioporto (or certain other companies you write about, for that matter) than it actually is. Maybe I got a little triggered, and that's why I mentioned bioporto… but again, you did agree with me that it was bioporto that, strictly speaking, was the basis for your reply to the thread starter, right? And I also wrote in the reply that "[…] but that discussion [about bioporto] doesn't belong here". You then continue to talk about bioporto in another reply, and I react to that again, which I probably shouldn't have done. I have heard PME's fantasies about how fantastic and universally useful their ngal test is, at a time when PME knew very well that reality was somewhat different. Be careful not to trust too much what is said on such webcasts.
- ·3 päivää sittenMajor Shareholder Announcement https://www.globenewswire.com/news-release/2026/04/13/3272255/0/en/Major-Shareholder-Announcement.html·1 päivä sittenSorry in advance that this is not about BP. Look at AC, I have written to JJ and asked if it applies to both children and adults. For your information, it clearly states in the first message that it only applies to the children's film. He will not answer concretely, but insinuated that it did. I believe he is lying, just as he has done since he started as CEO at Acucort. I strongly doubt that the FDA approves both the children's and adult film at once. I have sold most of my shares at AC, because JJ has repeatedly been caught lying about his achievements. I have written about it on Shareville every time, so you can check it yourself. You shouldn't take my word for it, you can write to the FDA and ask if they are in the process of approving the oral film, for both children and adults, on one application. If they are not allowed to answer directly about an application, then you can add the following: has the FDA ever approved several different items on one application? If not, can they imagine a situation where it would ever be possible? One cannot see your holdings, so I assume that you have shares in Acucort, since you replied to me at AC. Just for the record, I don't care if one can see your holdings, it's just an observation.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
21 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenFollowing my post on 8. March, management's shareholdings in BioPorto are a strong optimistic signal, as stated in Carnegie's report page 48. Among the company's ten largest shareholders are CEO, CLO, former CEO, chairman and vice charirman. The ten largest shareholders hold approx. 33%. Since Martin Bundgaard first flagged his 5% on Monday, they are not included in Carnegie's overview. From my post on 8. March: 2026 could be a very good year for BioPorto: The sentiment for biotech on Wall Street has turned significantly at the beginning of 2026, and the IPO market (initial public offerings) shows clear signs of life after several years of dormancy. After a very quiet 2024 and a historically weak 2025, investors have returned with renewed optimism. The Chairman, Jens Due Olsen, has invested approx. 6 million kr. of his own funds in 2025 (at prices 1.34 and 1.07 in the two emissions). Remarkable for a company of BioPorto's size. * Signal: Chairmen in biotech companies rarely make million-dollar investments shortly before crucial clinical data, unless they have a very strong belief in the company's fundamental value and the preliminary observations from the studies. * Risk/Reward: He bought in at a time when the stock is close to its historical low, which suggests that he sees a significant asymmetric gain opportunity when the adult data is expected to land later in 2026 Carsten Buhl joined on 1. September 2025, as the new CEO, and already in November chose to invest approx. 500,000 kr. in the emission. * Insight: As CEO, he has direct responsibility for the execution of the clinical study for adults. His willingness to invest his own money so quickly after his employment is interpreted as him "liking what he sees" in the internal processes and in the dialogue with the American clinics.·1 päivä sitten · MuokattuFurther to your post Preston20, I would like to inform that it is known to those of us who have been with the stock for a longer time, that there are several people who comment on Bioporto because they at some point lost money on this stock. Instead of taking the loss like adult men, they lie down on their stomachs and pound their fists on the floor and cry like small annoying curling children, who again, and again and again, involve the rest of us in their losses, back when the king of clubs was a knave. Lord preserve us.·11 t sitten3d We are merely commenting on facts about a company that is not developing .... and patents that are soon expiring
- ·1 päivä sitten
- ·3 päivää sittenUntil the company can clearly demonstrate through large studies precisely how, and especially why in terms of more effective treatment and savings, the product should be used, it will not be sold in larger numbers. The test costs a fortune compared to the existing one, and there is no medicine one can give in connection with acute kidney injury - so why exactly use it, when fluids and medication will already be regulated? The product, after almost 15 years available and attempted to be sold, would sell itself, where the opposite is still the case, if it both saved lives and resulted in savings, but that is far from documented. Should it succeed in documenting the effect in a few years, the major players can simply offer a similar product, as the patents begin to expire this year.
- ·3 päivää sittenK1000 I think it's strange that you start discussing Bioporto, on another stock's page. You are apparently in doubt whether I know Bioporto's path to an FDA approval for children. The short version of why Bioporto chose to split the NGAL test into two. One for children and one for adults. Bioporte had for an incredibly many years tried to get the NGAL test approved in the USA, as a combined test, but was rejected, with a standard text, that there was not enough evidence etc. Only when Antony became CEO, (he is a US citizen) did he get a dialogue with the FDA, and here the FDA suggested that if Bioporto were to have a chance of getting an approval, the test should be split into two, as it is today. The FDA stipulated that it should be the children's test they should run through a study first, if the FDA were to receive an application form. So it was not by Bioporto's good will or suggestion that the test was split into two, it was the FDA that suggested it, and it was the FDA that stipulated that it should be the test for children that they would look at first. When the FDA says jump, you ask how high. There are several webcasts where PME details the process with the FDA. You'll have to find them yourself on You tube.·1 päivä sitten@3D... I apologize if my reply in Acucort (the forum) came across as if I wanted to discuss bioporto. That was not the intention, but when you wrote that an FDA application would now take a long time, because the FDA had decided to divide the study into a pediatric and an adult study respectively, I got the idea that you were confusing acucort's situation with bioporto's ditto; which you also agreed with me on. Perhaps I should not have elaborated on how and why the two situations are different, but merely stuck to explaining what you had misunderstood regarding acucort's application process. I then forgot the latter part here in my first reply, but wrote it shortly after in another. I don't think I expressed that I doubt whether you are familiar with bioporto's application process… and I naturally have nothing against debate participants maintaining optimism regarding the companies they are invested in, but if I'm to be completely honest, it's a bit difficult to read post after post where you distort realities, so that reality appears brighter for bioporto (or certain other companies you write about, for that matter) than it actually is. Maybe I got a little triggered, and that's why I mentioned bioporto… but again, you did agree with me that it was bioporto that, strictly speaking, was the basis for your reply to the thread starter, right? And I also wrote in the reply that "[…] but that discussion [about bioporto] doesn't belong here". You then continue to talk about bioporto in another reply, and I react to that again, which I probably shouldn't have done. I have heard PME's fantasies about how fantastic and universally useful their ngal test is, at a time when PME knew very well that reality was somewhat different. Be careful not to trust too much what is said on such webcasts.
- ·3 päivää sittenMajor Shareholder Announcement https://www.globenewswire.com/news-release/2026/04/13/3272255/0/en/Major-Shareholder-Announcement.html·1 päivä sittenSorry in advance that this is not about BP. Look at AC, I have written to JJ and asked if it applies to both children and adults. For your information, it clearly states in the first message that it only applies to the children's film. He will not answer concretely, but insinuated that it did. I believe he is lying, just as he has done since he started as CEO at Acucort. I strongly doubt that the FDA approves both the children's and adult film at once. I have sold most of my shares at AC, because JJ has repeatedly been caught lying about his achievements. I have written about it on Shareville every time, so you can check it yourself. You shouldn't take my word for it, you can write to the FDA and ask if they are in the process of approving the oral film, for both children and adults, on one application. If they are not allowed to answer directly about an application, then you can add the following: has the FDA ever approved several different items on one application? If not, can they imagine a situation where it would ever be possible? One cannot see your holdings, so I assume that you have shares in Acucort, since you replied to me at AC. Just for the record, I don't care if one can see your holdings, it's just an observation.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 2 913 | - | - | ||
| 12 126 | - | - | ||
| 1 000 | - | - | ||
| 3 727 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 85 506 | 85 506 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 85 506 | 85 506 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
2025 Q4 -tulosraportti
21 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenFollowing my post on 8. March, management's shareholdings in BioPorto are a strong optimistic signal, as stated in Carnegie's report page 48. Among the company's ten largest shareholders are CEO, CLO, former CEO, chairman and vice charirman. The ten largest shareholders hold approx. 33%. Since Martin Bundgaard first flagged his 5% on Monday, they are not included in Carnegie's overview. From my post on 8. March: 2026 could be a very good year for BioPorto: The sentiment for biotech on Wall Street has turned significantly at the beginning of 2026, and the IPO market (initial public offerings) shows clear signs of life after several years of dormancy. After a very quiet 2024 and a historically weak 2025, investors have returned with renewed optimism. The Chairman, Jens Due Olsen, has invested approx. 6 million kr. of his own funds in 2025 (at prices 1.34 and 1.07 in the two emissions). Remarkable for a company of BioPorto's size. * Signal: Chairmen in biotech companies rarely make million-dollar investments shortly before crucial clinical data, unless they have a very strong belief in the company's fundamental value and the preliminary observations from the studies. * Risk/Reward: He bought in at a time when the stock is close to its historical low, which suggests that he sees a significant asymmetric gain opportunity when the adult data is expected to land later in 2026 Carsten Buhl joined on 1. September 2025, as the new CEO, and already in November chose to invest approx. 500,000 kr. in the emission. * Insight: As CEO, he has direct responsibility for the execution of the clinical study for adults. His willingness to invest his own money so quickly after his employment is interpreted as him "liking what he sees" in the internal processes and in the dialogue with the American clinics.·1 päivä sitten · MuokattuFurther to your post Preston20, I would like to inform that it is known to those of us who have been with the stock for a longer time, that there are several people who comment on Bioporto because they at some point lost money on this stock. Instead of taking the loss like adult men, they lie down on their stomachs and pound their fists on the floor and cry like small annoying curling children, who again, and again and again, involve the rest of us in their losses, back when the king of clubs was a knave. Lord preserve us.·11 t sitten3d We are merely commenting on facts about a company that is not developing .... and patents that are soon expiring
- ·1 päivä sitten
- ·3 päivää sittenUntil the company can clearly demonstrate through large studies precisely how, and especially why in terms of more effective treatment and savings, the product should be used, it will not be sold in larger numbers. The test costs a fortune compared to the existing one, and there is no medicine one can give in connection with acute kidney injury - so why exactly use it, when fluids and medication will already be regulated? The product, after almost 15 years available and attempted to be sold, would sell itself, where the opposite is still the case, if it both saved lives and resulted in savings, but that is far from documented. Should it succeed in documenting the effect in a few years, the major players can simply offer a similar product, as the patents begin to expire this year.
- ·3 päivää sittenK1000 I think it's strange that you start discussing Bioporto, on another stock's page. You are apparently in doubt whether I know Bioporto's path to an FDA approval for children. The short version of why Bioporto chose to split the NGAL test into two. One for children and one for adults. Bioporte had for an incredibly many years tried to get the NGAL test approved in the USA, as a combined test, but was rejected, with a standard text, that there was not enough evidence etc. Only when Antony became CEO, (he is a US citizen) did he get a dialogue with the FDA, and here the FDA suggested that if Bioporto were to have a chance of getting an approval, the test should be split into two, as it is today. The FDA stipulated that it should be the children's test they should run through a study first, if the FDA were to receive an application form. So it was not by Bioporto's good will or suggestion that the test was split into two, it was the FDA that suggested it, and it was the FDA that stipulated that it should be the test for children that they would look at first. When the FDA says jump, you ask how high. There are several webcasts where PME details the process with the FDA. You'll have to find them yourself on You tube.·1 päivä sitten@3D... I apologize if my reply in Acucort (the forum) came across as if I wanted to discuss bioporto. That was not the intention, but when you wrote that an FDA application would now take a long time, because the FDA had decided to divide the study into a pediatric and an adult study respectively, I got the idea that you were confusing acucort's situation with bioporto's ditto; which you also agreed with me on. Perhaps I should not have elaborated on how and why the two situations are different, but merely stuck to explaining what you had misunderstood regarding acucort's application process. I then forgot the latter part here in my first reply, but wrote it shortly after in another. I don't think I expressed that I doubt whether you are familiar with bioporto's application process… and I naturally have nothing against debate participants maintaining optimism regarding the companies they are invested in, but if I'm to be completely honest, it's a bit difficult to read post after post where you distort realities, so that reality appears brighter for bioporto (or certain other companies you write about, for that matter) than it actually is. Maybe I got a little triggered, and that's why I mentioned bioporto… but again, you did agree with me that it was bioporto that, strictly speaking, was the basis for your reply to the thread starter, right? And I also wrote in the reply that "[…] but that discussion [about bioporto] doesn't belong here". You then continue to talk about bioporto in another reply, and I react to that again, which I probably shouldn't have done. I have heard PME's fantasies about how fantastic and universally useful their ngal test is, at a time when PME knew very well that reality was somewhat different. Be careful not to trust too much what is said on such webcasts.
- ·3 päivää sittenMajor Shareholder Announcement https://www.globenewswire.com/news-release/2026/04/13/3272255/0/en/Major-Shareholder-Announcement.html·1 päivä sittenSorry in advance that this is not about BP. Look at AC, I have written to JJ and asked if it applies to both children and adults. For your information, it clearly states in the first message that it only applies to the children's film. He will not answer concretely, but insinuated that it did. I believe he is lying, just as he has done since he started as CEO at Acucort. I strongly doubt that the FDA approves both the children's and adult film at once. I have sold most of my shares at AC, because JJ has repeatedly been caught lying about his achievements. I have written about it on Shareville every time, so you can check it yourself. You shouldn't take my word for it, you can write to the FDA and ask if they are in the process of approving the oral film, for both children and adults, on one application. If they are not allowed to answer directly about an application, then you can add the following: has the FDA ever approved several different items on one application? If not, can they imagine a situation where it would ever be possible? One cannot see your holdings, so I assume that you have shares in Acucort, since you replied to me at AC. Just for the record, I don't care if one can see your holdings, it's just an observation.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 2 913 | - | - | ||
| 12 126 | - | - | ||
| 1 000 | - | - | ||
| 3 727 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 85 506 | 85 506 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 85 506 | 85 506 | 0 | 0 |